Notify Therapeutics is developing a non-hormonal, first-in-class drug that induces factors regulating the NRF2 pathway to drive follicle activation and egg maturation. The company aims to treat women with diminished ovarian reserve (DOR) and to offer an alternative to standard hormone therapies. Early preclinical work activated NRF2 in mice and in ovarian tissue from women with DOR, stimulating egg maturation and increasing successful pregnancies in the rodent study. Notify plans to use the new funding to select the best-suited molecule and advance it into clinical phases. The program focuses on the hormone-independent phase of ovarian follicle development, prioritizing efficiency, safety, and patient well-being. Founded on Professor Karin Lykke-Hartmann’s research, the company positions its approach as potentially transformative for infertility treatment outcomes.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2023